NaviFUS Corporation
TTPEX:687219.65
TWD
-1.10
(-5.30%)
ISIN
TW0006872005
Return %
Stock
S&P 500
1Y
-4.61
14.20
3Y
-18.57
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Chen Yu Lung
- Full Time Employees
- 20
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- No. 246, Chengde Rd. Taipei TP Taiwan 103
- IPO Date
- Mar 7, 2015
- Website
- navifus.com
- Similar Companies
- Business
- NaviFUS Corp. is a Taiwan-based medical device company specializing in the development, manufacture, and sale of focused ultrasound systems and related therapeutic technologies. The company's core products primarily encompass non-invasive focused ultrasound equipment designed for tumor ablation and other therapeutic applications within oncology and other medical fields. NaviFUS provides advanced medical devices that integrate precise imaging guidance with high-intensity ultrasound energy to target pathological tissue without surgical intervention. Its product portfolio includes its proprietary NaviFUS focused ultrasound system, which supports clinical applications such as brain tumor treatment and other neurological disorders. Founded in 2012 and headquartered in Taipei, Taiwan, NaviFUS operates primarily within the healthcare and medical technology industry, targeting hospitals, medical centers, and research institutions across Taiwan and expanding in global markets through collaborations and distribution partnerships. The company's efforts emphasize innovation in non-invasive therapies as an alternative to traditional surgical and radiotherapy methods. In the past 1-2 years, NaviFUS has actively advanced its strategic development through new partnerships and technological advancements. Notably, the company has strengthened alliances with academic and clinical institutions to enhance R&D capabilities and clinical trial pipelines. NaviFUS has also been developing next-generation products aimed at expanding indications and improving system efficiency. While no major rebranding or corporate restructuring has been reported recently, NaviFUS continues to focus on broadening its global footprint and accelerating commercialization efforts for its flagship focused ultrasound platform. Overall, NaviFUS operates within the medical devices segment of the healthcare industry, providing highly specialized, cutting-edge focused ultrasound therapeutic systems. It serves a niche market primarily in oncology and neurological therapy, with a growing presence in international medical device markets. The company remains committed to innovation-driven growth and expanding its portfolio of non-invasive treatment technologies. This description reflects NaviFUS Corp.'s current business operations, product offerings, industry focus, and recent strategic initiatives as of late 2025 based on publicly available information.